A Double-Blind, Randomised, Single Centre, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of a Single Subcutaneous Implant of EPT 1647 in Patients Suffering from Recurrent Polymorphous Light Eruption
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Afamelanotide (Primary)
- Indications Polymorphus light eruptions
- Focus Therapeutic Use
- Acronyms EP012
- Sponsors Clinuvel Pharmaceuticals
- 07 Jul 2016 New trial record